Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs

Molecular Pharmaceutics

Volumn 12, Issue 8, 2015, Pages 2582-2593

  Miller, Danforth P ^a   Tan, Trixie ^a   Tarara, Thomas E ^a   Nakamura, John ^a   Malcolmson, Richard J ^a   Weers, Jeffry G ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

amorphous; pulmonary delivery; spray drying; TOBI Podhaler

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GEL PHASE PHOSPHOLIPID; PHOSPHOLIPID DERIVATIVE; PLACEBO; TOBRAMYCIN; TOBRAMYCIN HYDROCHLORIDE; TOBRAMYCIN SULFATE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; NANOPARTICLE; POWDER;

AEROSOL; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRY POWDER INHALER; GEL; GLASS TRANSITION TEMPERATURE; LIQUID CRYSTAL; METERED DOSE INHALER; PARTICLE SIZE; PHYSICAL CHEMISTRY; POROSITY; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SURFACE PROPERTY; TOBRAMYCIN INHALATION POWDER; X RAY PHOTOELECTRON SPECTROSCOPY; X RAY POWDER DIFFRACTION; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; MEDICINAL CHEMISTRY; POWDER; PROCEDURES;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRY POWDER INHALERS; HUMANS; LUNG DISEASES; NANOPARTICLES; PARTICLE SIZE; POWDERS; TOBRAMYCIN;

EID: 84938352055     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00147     Document Type: Article

References (67)

1. Konstan, M. W.; Flume, P. A.; Kappler, M.; Chiron, R.; Higgins, M.; Brockhaus, F.; Zhang, J.; Angyalosi, G.; He, E.; Geller, D. E.; Investigators, E. S. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial J. Cystic Fibrosis 2011, 10 (1) 54-61
2. Harrison, M. J.; McCarthy, M.; Fleming, C.; Hickey, C.; Shortt, C.; Eustace, J. A.; Murphy, D. M.; Plant, B. J. Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF) J. Cystic Fibrosis 2014, 13 (6) 692-698
3. Harrison, M. J.; McCarthy, M.; Fleming, C.; Shortt, C.; Hickey, C.; Eustace, J. A.; Murphy, D. M.; Plant, B. J. Improved tolerability, adherence and reduced intravenous (IV) antibiotic usage in CF patients receiving inhaled versus nebulised antibiotic prophylaxis. A real world comparison of tobramycin inhaled powder (TIP) and tobramycin inhaled solution (TIS) [abstract #74] J. Cystic Fibrosis 2013, 12, S67
4. Nash, E. F.; Ahitan, B.; Brown, C. J.; Thakrar, K.; Carrolan, V.; Rashid, R.; Whitehouse, J. L. Comparison of pharmacy prescription refill frequency in CF adults before and after switching from tobramycin inhalation solution (TIS) to TOBI Podhaler-'Real world' evidence of improved adherence [abstract #68] J. Cystic Fibrosis 2013, 12, S65
5. Brown, C. J.; Nash, E. F.; Cameron, S.; Rashid, R.; Whitehouse, J. L. Clinical outcomes and patient satisfaction following initiation of the TOBI Podhaler in CF adults [abstract #67] J. Cystic Fibrosis 2013, 12, S65
6. Harrison, M. J.; McCarthy, M.; Fleming, C.; Hickey, C.; Shortt, C.; Eustace, J. A.; Murphy, D. M.; Plant, B. J. Improved adherence, tolerability and low discontinuation rate in a prospective real world study with tobramycin inhaled powder (TIP) compared to tobramycin inhaled solution (TIS) in cystic fibrosis (CF) Ir. J. Med. Sci. 2012, 181, S403-S403
7. Geller, D. E.; Weers, J.; Heuerding, S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology J. Aerosol Med. Pulm. Drug Delivery 2011, 24 (4) 175-82
8. Weers, J.; Tarara, T. The PulmoSphere platform for pulmonary drug delivery Ther. Delivery 2014, 5 (3) 277-295
9. Tarara, T. E.; Weers, J. G.; Venthoye, G. Pulmonary delivery of aminoglycosides. U.S. Patent 7,368,102. 2008.
10. Masters, K. Spray Drying Handbook; Halstead Press: Sydney, Australia, 1985.
11. Kabalnov, A.; Weers, J.; Arlauskas, R.; Tarara, T. Phospholipids as emulsion stabilizers 0.1. Interfacial-tensions Langmuir 1995, 11 (8) 2966-2974
12. Kabalnov, A.; Tarara, T.; Arlauskas, R.; Weers, J. Phospholipids as emulsion stabilizers 0.2. Phase behavior versus emulsion stability J. Colloid Interface Sci. 1996, 184 (1) 227-235
13. Haynes, A.; Nakamura, J.; Heng, C.; Heuerding, S.; Thompson, G.; Malcolmson, R. Aerosol performance of tobramycin inhalation powder Respir. Drug Delivery 2010, 3, 701-706
14. Haynes, A.; Ament, B.; Heng, C.; Le, J.; Ung, K.; Rao, R.; Malcolmson, R.; Weers, J.; Pavkov, R.; Heuerding, S.; Geller, D. In vitro aerosol delivery performance of tobramycin powder for inhalation (TOBI Podhaler) using inspiratory flows from cystic fibrosis patients Pediatr. Pulmonol. 2013, 48 (S36) 352
15. Saxena, V.; Panicucci, R.; Joshi, Y.; Garad, S. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates J. Pharm. Sci. 2009, 98 (6) 1962-79
16. Creuwels, L. A.; van Golde, L. M.; Haagsman, H. P. The pulmonary surfactant system: Biochemical and clinical aspects Lung 1997, 175 (1) 1-39
17. Washburn, E. W. The dynamics of capillary flow Phys. Rev. 1921, 17 (3) 273-283
18. 〈616〉 Bulk density and tapped density of powders. United States Pharmacopeia, USP 29; 2006.
19. Vehring, R. Pharmaceutical particle engineering via spray drying Pharm. Res. 2008, 25 (5) 999-1022
20. Tsapis, N.; Bennett, D.; Jackson, B.; Weitz, D. A.; Edwards, D. A. Trojan particles: large porous carriers of nanoparticles for drug delivery Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (19) 12001-5
21. Weers, J. G.; Tarara, T. E.; Clark, A. R. Design of fine particles for pulmonary drug delivery Expert Opin. Drug Delivery 2007, 4, 297-313
22. Ivey, J. W.; Vehring, R. The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development Comput. Chem. Eng. 2010, 34 (7) 1036-1040
23. Krafft, M. P.; Riess, J. G.; Weers, J. G., The design and engineering of oxygen-delivering fluorocarbon emulsions. In Submicron Emulsions in Drug Targeting and Delivery; Benita, S., Ed.; Harwood Academic Publishers: Amsterdam, 1998; pp 235-333.
24. Weers, J. G. Dispersible powders for inhalation applications Innov. Pharm. Technol. 2000, 1 (7) 111-116
25. Duddu, S. P.; Sisk, S. A.; Walter, Y. H.; Tarara, T. E.; Trimble, K. R.; Clark, A. R.; Eldon, M. A.; Elton, R. C.; Pickford, M.; Hirst, P. H.; Newman, S. P.; Weers, J. G. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere (R) powder Pharm. Res. 2002, 19 (5) 689-695
26. (R) particles are unaffected by a subject's inhalation maneuver J. Aerosol Med. Pulm. Drug Delivery 2013, 26 (1) 56-68
27. Vehring, R.; Foss, W. R.; Lechuga-Ballesteros, D. Particle formation in spray drying J. Aerosol Sci. 2007, 38 (7) 728-746
28. Dunbar, C. Porous Particles for Inhalation: The Science Behind Their Improved Dispersibility. In Respiratory Drug Delivery X; Dalby, R. N.; Byron, P. R.; Peart, J.; Suman, J. D.; Farr, S. J., Eds.; RDD: Richmond, VA, 2006; pp 307-313.
29. Chew, N. Y. K.; Chan, H. K. Use of solid corrugated particles to enhance powder aerosol performance Pharm. Res. 2001, 18 (11) 1570-1577
30. Hausner, H. H. Friction conditions in a mass of metal powder Int. J. Powder Metall. 1967, 3, 7-13
31. Carr, R. L. Evaluating flow properties of solids Chem. Eng. 1965, 72 (3) 163-168
32. Carr, R. L. Classifying flow properties of solids Chem. Eng. 1965, 72 (3) 69-72
33. Edwards, D. A.; Hanes, J.; Caponetti, G.; Hrkach, J.; Ben-Jebria, A.; Eskew, M. L.; Mintzes, J.; Deaver, D.; Lotan, N.; Langer, R. Large Porous Particles for Pulmonary Drug Delivery Science 1997, 276 (5320) 1868-1872
34. Vanbever, R.; Mintzes, J. D.; Wang, J.; Nice, J.; Chen, D. H.; Batycky, R.; Langer, R.; Edwards, D. A. Formulation and physical characterization of large porous particles for inhalation Pharm. Res. 1999, 16 (11) 1735-1742
35. Meenach, S. A.; Vogt, F. G.; Anderson, K. W.; Hilt, J. Z.; McGarry, R. C.; Mansour, H. M. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols Int. J. Nanomed. 2013, 8, 275-93
36. Li, X.; Vogt, F. G.; Hayes, D., Jr.; Mansour, H. M. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery Eur. J. Pharm. Sci. 2014, 52, 191-205
37. Parlati, C.; Colombo, P.; Buttini, F.; Young, P. M.; Adi, H.; Ammit, A. J.; Traini, D. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency Pharm. Res. 2009, 26 (5) 1084-92
38. Hartel, R. W.; Shastry, A. V. Sugar crystallization in food-products Crit. Rev. Food Sci. Nutr. 1991, 30 (1) 49-112
39. Van Scoik, K. G.; Carstensen, J. T. Nucleation phenomena in amorphous sucrose systems Int. J. Pharm. 1990, 58 (3) 185-196
40. Wiener, M. C.; Suter, R. M.; Nagle, J. F. Structure of the fully hydrated gel phase of dipalmitoylphosphatidylcholine Biophys. J. 1989, 55 (2) 315-325
41. Sun, W. J.; Tristram-Nagle, S.; Suter, R. M.; Nagle, J. F. Structure of gel phase saturated lecithin bilayers: Temperature and chain length dependence Biophys. J. 1996, 71 (2) 885-891
42. Nagase, H.; Ueda, H.; Nakagaki, M. Effect of water on lamellar structure of DPPC/sugar systems Bichim. Biophys. Acta, Biomembr. 1997, 1328 (2) 197-206
43. Lenné, T.; Garvey, C. J.; Koster, K. L.; Bryant, G. Effects of sugars on lipid bilayers during dehydration-SAXS/WAXS measurements and quantitative model J. Phys. Chem. B 2009, 113 (8) 2486-2491
44. Lenné, T.; Bryant, G.; Holcomb, R.; Koster, K. L. How much solute is needed to inhibit the fluid to gel membrane phase transition at low hydration? Biochim. Biophys. Acta 2007, 1768 (5) 1019-22
45. Cevc, G. Polymorphism of the bilayer-membranes in the ordered phase and the molecular-origin of the lipid pretransition and rippled lamellae Biochim. Biophys. Acta 1991, 1062 (1) 59-69
46. Nagle, J. F.; Wilkinson, D. A. Lecithin bilayers-density-measurements and molecular-interactions Biophys. J. 1978, 23 (2) 159-175
47. Koynova, R.; Caffrey, M. Phases and phase transitions of the phosphatidylcholines Biochim. Biophys. Acta, Rev. Biomembr. 1998, 1376 (1) 91-145
48. Cevc, G. Phospholipids Handbook; Taylor & Francis: Oxford, U.K., 1993.
49. Matsuki, H.; Okuno, H.; Sakano, F.; Kusube, M.; Kaneshina, S. Effect of deuterium oxide on the thermodynamic quantities associated with phase transitions of phosphatidylcholine bilayer membranes Biochim. Biophys. Acta, Biomembr. 2005, 1712 (1) 92-100
50. Jia, Y. M.; Joly, H.; Leek, D. M.; Demetzos, C.; Omri, A. The effect of aminoglycoside antibiotics on the thermodynamic properties of liposomal vesicles J. Liposome Res. 2010, 20 (1) 84-96
51. Colome, C.; Alsina, M. A.; Busquets, M. A.; Haro, I.; Reig, F. Interaction of aminoglycosides and colistin with model membranes-liposomes and monolayers Int. J. Pharm. 1993, 90 (1) 59-71
52. Crowe, J. H. Trehalose and anhydrobiosis: the early work of J. S. Clegg J. Exp. Biol. 2008, 211 (Pt 18) 2899-900
53. Crowe, J. H. Anhydrobiosis: an unsolved problem Am. Nat. 1971, 105 (946) 563-573
54. Crowe, J. H.; Crowe, L. M. Induction of anhydrobiosis: membrane changes during drying Cryobiology 1982, 19 (3) 317-28
55. Crowe, J. H. Anhydrobiosis: an unsolved problem Plant Cell Environ. 2014, 37 (7) 1491-3
56. Crowe, J. H.; Hoekstra, F. A.; Crowe, L. M. Anhydrobiosis Annu. Rev. Physiol. 1992, 54, 579-99
57. Crowe, L. M. Lessons from nature: the role of sugars in anhydrobiosis Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 2002, 131 (3) 505-13
58. Crowe, L. M.; Crowe, J. H. Trehalose and dry dipalmitoylphosphatidylcholine revisited Biochim. Biophys. Acta 1988, 946 (2) 193-201
59. Bryant, G.; Koster, K. L.; Wolfe, J. Membrane behaviour in seeds and other systems at low water content: the various effects of solutes Seed Sci. Res. 2001, 11 (1) 17-25
60. Bryant, G.; Wolfe, J. Interfacial forces in cryobiology and anhydrobiology Cryo-Lett. 1992, 13 (1) 23-36
61. Kent, B.; Hunt, T.; Darwish, T. A.; Hauss, T.; Garvey, C. J.; Bryant, G. Localization of trehalose in partially hydrated DOPC bilayers: insights into cryoprotective mechanisms J. R. Soc. Interface 2014, 11 (95) 20140069
62. Koster, K. L.; Maddocks, K. J.; Bryant, G. Exclusion of maltodextrins from phosphatidylcholine multilayers during dehydration: effects on membrane phase behaviour Eur. Biophys. J. 2003, 32 (2) 96-105
63. Koster, K. L.; Lei, Y. P.; Anderson, M.; Martin, S.; Bryant, G. Effects of vitrified and nonvitrified sugars on phosphatidylcholine fluid-to-gel phase transitions Biophys. J. 2000, 78 (4) 1932-1946
64. Giordano, D.; Potuzak, M.; Romano, C.; Dingwell, D. B.; Nowak, M. Viscosity and glass transition temperature of hydrous melts in the system CaAl2Si2O8-CaMgSi2O6 Chem. Geol. 2008, 256 (3-4) 203-215
65. Alpert, P. The limits and frontiers of desiccation-tolerant life Integr. Comp. Biol. 2005, 45 (5) 685-695
66. Moynihan, C. T., Structural Relaxation and the Glass Transition. In Structure, Dynamics and Properties of Silicate Melts; Stebbins, J. F.; McMillan, P. F.; Dingwell, D. B., Eds.; Mineralogical Society of America: Chelsea, MI, 1995; Vol. 32, pp 1-19.
67. Hancock, B. C.; Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 1997, 86 (1) 1-12